A new drug that regrows teeth, developed by Japanese researchers led by Katsu Takahashi from Kitano Hospital, is about to enter human trials. This intravenous drug blocks the USAG-1 protein, which suppresses tooth growth, triggering new tooth development.
Human trials start in September, following successful tests on ferrets and mice with no serious side effects.
Due to the 97 percent similarity in the USAG-1 protein function between humans and other species, researchers are optimistic about its effectiveness in humans.
The initial trial will involve adults missing at least one molar, while subsequent trials will target children aged two to seven with congenital tooth deficiencies and older adults missing one to five teeth due to environmental factors.
Takahashi and his team predict the drug could be available to consumers by 2030. This development builds on years of research, including regenerative tooth fillings and stem cell technology to repair dental tissue.
#MaltaDaily